Evidence Grade: C — One of the few research peptides with a full program of randomized, double-blind, placebo-controlled human trials. Safety data is strong; efficacy data is weak, and the largest trial did not beat placebo on weight loss. Graded C on efficacy, not on quality of evidence.

What it is

AOD-9604 is a synthetic 16-amino-acid peptide corresponding to residues 177–191 of human growth hormone (the C-terminal region), with a tyrosine added at the N-terminus for stability — hence the name “hexadecapeptide.” It was developed by Metabolic Pharmaceuticals (Melbourne, Australia) out of work at Monash University as an anti-obesity candidate.

Proposed mechanism

The C-terminal region of hGH was identified in the 1990s as the segment responsible for GH’s lipolytic (fat-mobilizing) effect. AOD-9604 was designed to keep that effect without GH’s growth-promoting or insulin-antagonizing actions. In mice it increased fat oxidation and reduced body fat without raising IGF-1. The β3-adrenergic receptor appears involved: chronic treatment lost its effect in β3-AR knockout mice, though the authors concluded the action is not mediated directly through that receptor.

What the literature shows

Animal: Reduced body weight and fat mass in obese (ob/ob) mice after 14 days of daily treatment, with restoration of β3-AR expression in fat tissue to lean-mouse levels. No effect on IGF-1.

Human: Six randomized, double-blind, placebo-controlled trials were run, roughly 900 participants in total, using oral formulations. An early Phase IIa trial reported about 2.6 kg loss versus 0.8 kg on placebo at 12 weeks, with a non-linear dose response (higher doses did worse). The final, larger Phase IIb trial (2007), which added a diet-and-exercise program for all participants, found no significant difference from placebo, and obesity development was discontinued. A 2013 compilation of the safety data across all six trials reported tolerability indistinguishable from placebo: no IGF-1 elevation, no impaired glucose tolerance, no anti-AOD9604 antibodies, and no serious adverse events attributed to the drug. Later work on cartilage and osteoarthritis is limited to rabbit models.

Regulatory status

Not approved as a drug anywhere. In 2014 AOD-9604 received self-affirmed GRAS (“generally recognized as safe”) status in the US for use as a food ingredient — a category unrelated to drug approval. Listed by WADA under S2 (peptide hormones, growth factors and related substances).

Gaps and caveats

• The best-controlled human evidence is negative on efficacy; earlier positive signals came from smaller trials and did not hold up
• All human trials used oral dosing; the data says nothing about other routes
• GRAS status is routinely misrepresented as FDA approval; it is not
• Cartilage and joint claims rest on rabbit models only
• The safety compilation was authored by people connected to the compound’s commercial development

Key references

Moré MI, Kenley D. Journal of Endocrinology and Metabolism, 2014 — safety and metabolism review (industry-authored)

Heffernan M et al. Endocrinology, 2001 — obese and β3-AR knockout mice

Stier H, Vos E, Kenley D. Journal of Endocrinology and Metabolism, 2013 — safety and tolerability across six human trials

Misra M, Kelley DE. Therapeutic Advances in Endocrinology and Metabolism, 2013 — obesity pharmacotherapy review including the AOD-9604 trial summary